The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Canwell Biotech Ltd. has described antibody-drug conjugates (ADCs) comprising an antibody covalently linked to a Toll-like receptor 7 (TLR7) and TLR8 agonist through a cleavable or noncleavable linker ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

Myris Therapeutics™ emerged from stealth today to announce its strategic focus. Myris, formerly known as BioHybrid Solutions, ...

In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...